Hemorrhagic Complications Following Trabecular Bypass Microstent Surgery in the Setting of Antithrombotic Therapy
- PMID: 36795533
- DOI: 10.1097/IJG.0000000000002173
Hemorrhagic Complications Following Trabecular Bypass Microstent Surgery in the Setting of Antithrombotic Therapy
Abstract
Prcis: In this retrospective study, the use of chronic antithrombotic therapy (ATT) did not increase the risk of hemorrhagic complications after trabecular bypass microstent surgery and phacoemulsification. Stent type and female sex were associated with hyphema.
Purpose: To report the incidence of hemorrhagic complications after trabecular bypass microstent surgery and phacoemulsification with and without (ATT).
Methods: Retrospective case series on glaucoma patients on chronic ATT who underwent trabecular bypass microstent surgery (iStent, iStent inject, and Hydrus) combined with phacoemulsification between 2013 and 2019 with ≥3-month follow-up. The primary outcome measure was the incidence of hemorrhagic complications within a 3-month postoperative period. Generalized estimating equations were created to account for inter-eye correlation and logistic regression analysis was performed to identify factors predictive of hemorrhagic complications.
Results: Of 333 patients (435 eyes), 161 patients (211 eyes) were on ATT and 172 patients (224 eyes) were not on ATT; both groups were similar in age and baseline ocular characteristics. The only hemorrhagic complication was hyphema, which occurred in 84 (19.3%) eyes (41 ATT, 43 non-ATT eyes; P = 1.00). Onset was at postoperative day 1 in 98.8% of eyes, with a duration of 1 week in 73.8% of eyes, without difference between ATT and non-ATT groups. Hyphema was most common with Hydrus microstent (36.4%) versus iStent (19.9%) and iStent inject (8.5%) ( P = 0.003). In the multivariate model, the female sex was a predictor of hyphema [hazard ratio (HR) = 2.062; P = 0.009], iStent inject was protective against hyphema (HR = 0.379; P = 0.033), whereas Hydrus did not reach statistical significance (HR = 2.007; P = 0.081). Age, systemic comorbidities, ATT use, and baseline ocular characteristics were not significant predictors.
Conclusions: Hemorrhagic complications after trabecular bypass microstent surgery were limited to transient hyphema and were not associated with chronic ATT use. Stent type and female sex were associated with hyphema.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Disclosure: DL: Consultant: Allergan, Inc. Research: Allergan, Inc. Speaker: Glaukos Corp. JSM: Consultant: AbbVie, Aerie, Avisi, Glaukos, Haag Streit, MicroOptx, Olleyes; Research: AbbVie, Aerie, Equinox, Glaukos, Diopsys, Haag Streit, Laboratories Thea, Nicox, Olleyes, Santen. NNK: Research: Allergan, Inc. MRM: Consultant: Alcon, Allergan, Bausch and Lomb, Glaukos, Aerie, and Qura; Speaker: Alcon, Allergan, Aerie, and Bausch and Lomb. AGS: Research: AbbVie, Inc. Consultant: AbbVie, Inc. American Glaucoma Society Mentoring for Advancement of Physician Scientists Grant. The remaining authors declare no conflict of interest.
Similar articles
-
Risk factors for hyphema following goniotomy or trabecular bypass stent placement combined with phacoemulsification.Graefes Arch Clin Exp Ophthalmol. 2025 Mar;263(3):781-786. doi: 10.1007/s00417-024-06647-y. Epub 2024 Oct 5. Graefes Arch Clin Exp Ophthalmol. 2025. PMID: 39367280
-
Intraocular Pressure After Cataract Surgery Combined With Ab Interno Trabeculectomy Versus Trabecular Micro-bypass Stent: An Intrasubject Same-surgeon Comparison.J Glaucoma. 2020 Sep;29(9):773-782. doi: 10.1097/IJG.0000000000001547. J Glaucoma. 2020. PMID: 32404618
-
A Prospective Analysis of iStent Inject Microstent Implantation: Surgical Outcomes, Endothelial Cell Density, and Device Position at 12 Months.J Glaucoma. 2020 Aug;29(8):639-647. doi: 10.1097/IJG.0000000000001546. J Glaucoma. 2020. PMID: 32433094
-
Ab interno trabecular bypass surgery with iStent for open-angle glaucoma.Cochrane Database Syst Rev. 2019 Mar 28;3(3):CD012743. doi: 10.1002/14651858.CD012743.pub2. Cochrane Database Syst Rev. 2019. PMID: 30919929 Free PMC article.
-
Trabecular micro-bypass shunt (iStent®): basic science, clinical, and future).Middle East Afr J Ophthalmol. 2015 Jan-Mar;22(1):30-7. doi: 10.4103/0974-9233.148346. Middle East Afr J Ophthalmol. 2015. PMID: 25624671 Free PMC article. Review.
Cited by
-
Early to late explantation of Hydrus microstent MIGS device: A case series.Am J Ophthalmol Case Rep. 2024 Jul 20;36:102105. doi: 10.1016/j.ajoc.2024.102105. eCollection 2024 Dec. Am J Ophthalmol Case Rep. 2024. PMID: 39161375 Free PMC article.
-
Anticoagulation for Minimally Invasive Glaucoma Surgery: An American Glaucoma Society Survey.J Glaucoma. 2025 Feb 1;34(2):77-83. doi: 10.1097/IJG.0000000000002518. Epub 2024 Nov 18. J Glaucoma. 2025. PMID: 39792810
-
Risk factors for hyphema following goniotomy or trabecular bypass stent placement combined with phacoemulsification.Graefes Arch Clin Exp Ophthalmol. 2025 Mar;263(3):781-786. doi: 10.1007/s00417-024-06647-y. Epub 2024 Oct 5. Graefes Arch Clin Exp Ophthalmol. 2025. PMID: 39367280
References
-
- Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23:96–104.
-
- Yook E, Vinod K, Panarelli JF. Complications of micro-invasive glaucoma surgery. Curr Opin Ophthalmol. 2018;29:147–154.
-
- Fellman RL, Mattox C, Singh K, et al. American glaucoma society position paper: microinvasive glaucoma surgery. Ophthalmol Glaucoma. 2020;3:1–6.
-
- Le K, Saheb H. iStent trabecular micro-bypass stent for open-angle glaucoma. Clin Ophthalmol. 2014;8:1937–1945.
-
- Stein JD, Ruiz D Jr, Belsky D, et al. Longitudinal rates of postoperative adverse outcomes after glaucoma surgery among medicare beneficiaries 1994 to 2005. Ophthalmology. 2008;115:1109–1116; e1107.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources